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Interleukin (IL)-1 and IL-4 synergistically stimulate NF-IL6 activity and
IL-6 production in human mesangial cells.
Background. While interleukin (IL)-4 inhibits pro-inflammatory cyto-
kine expression by human monocytes, we have observed that it potentiates
IL-6 production by IL-1-activated human mesangial cells (MC). To study
the mechanism of this cell-type specific interaction between IL-1 and IL-4
in MC, we examined the effect of both cytokines on the activities of
nuclear factor kB (NF-kB) and nuclear factor IL-6 (NF-IL6), transcription
factors that are essential for IL-6 gene expression.
Methods. We evaluated IL-6 synthesis, mRNA expression, and mRNA
stability by ELISA, Northern analysis, and the actinomycin D method,
respectively. Activities of NF-kB and NF-IL6 were analyzed by gel shift
assay.
Results. IL-4 augmented the IL-1 stimulated IL-6 mRNA levels by about
threefold without altering mRNA stability. IL-1 treatment rapidly induced
the binding activity of NF-kB. In contrast, IL-4 did not affect basal and
IL-1-induced NF-kB activities. Both IL-1 and IL-4 stimulated NF-IL6
activity as early as 30 minutes after treatment. When MC were treated
with both cytokines together, marked activation of NF-IL6 was observed
at five hours.
Conclusions. These results suggest that simultaneous activation of NF-
kB and NF-IL6 is essential for IL-6 gene expression and that IL-1 and IL-4
cooperatively stimulate MC IL-6 production through their synergistic
activation of NF-IL6.
Leukocyte infiltration, cell proliferation, and accumula-
tion of extracellular matrix are characteristic pathological
changes in most forms of glomerulonephritis (GN). These
changes have important clinical implications, as they can
eventually proceed to glomerular sclerosis and loss of renal
function. Along with physical stress and high glucose
concentration, various cytokines have been shown to mod-
ulate cell growth, adhesion, chemotaxis, and metabolism of
matrix proteins. Former studies have postulated roles for
platelet-derived growth factor, interleukin (IL)-1, tumor
necrosis factor (TNF), IL-6, transforming growth factor b
(TGF-b), and monocyte chemoatractant protein 1
(MCP-1) in inflamed glomeruli using various lines of
indirect evidence [reviewed in 1].
Activated leukocytes, especially macrophages, can ac-
tively synthesize these cytokines and are probably the major
source of these mediators. However, cultured MC can
release amounts of IL-6 under IL-1 or TNF stimulation
comparable to macrophages [2]. In vivo, IL-6 synthesis by
MC has recently been shown at the ultrastructural level in
lupus nephritis [3]. IL-6 induces proliferation of cultured
MC [4], and IL-6 transgenic mice develop severe mesangial
proliferation [5]. In addition to intraglomerular IL-6 gene
expression, higher urinary levels of IL-6 have been shown in
patients with mesangioproliferative GN [4]. These results
support the possibility that IL-6 released by MC under
some stimuli may act in an autocrine manner and acceler-
ate glomerular injury. While IL-1 and TNF are potent
inducers of IL-6 production, other currently unknown
possible stimulators or modulators may also play a role.
IL-4, which was initially described as a B-cell maturation
factor derived from T-cells, is now known to have multiple
cell type-specific activities on non-hematopoietic as well as
hematopoietic cells, and it has also been proposed to play
a role in GN [6–8]. To pursue this possibility, in prior
studies we have examined the effects of IL-4 on MC
functions [9, 10]. Recently, we found that IL-4 potentiates
IL-6, IL-8, and MCP-1 production by IL-1-stimulated MC.
In contrast to this observation, IL-4 has been reported to
inhibit the expression of IL-6 and other pro-inflammatory
cytokines by activated human monocytes [11]. As both
monocytes and MC presumably play pivotal roles in glo-
merulonephritis, their differential response to IL-4 is of
great interest.
Expression of the IL-6 gene is thought to be regulated by
a number of 59 upstream putative cis-acting elements,
including glucocorticoid response elements, an AP-1 con-
sensus site, a multiple response element, an NF-IL6 bind-
ing site, and an NF-kB site [12]. Previous studies have
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reported that binding sites for NF-IL6 and NF-kB are
essential for the expression of IL-6 [13–16].
In the present study, we targeted the transcription factors
NF-kB and NF-IL6 to investigate the interaction between
IL-1 and IL-4 in human MC.
METHODS
Materials
Recombinant human IL-1a (2.21 3 107 U/mg) was
kindly provided by the Dainippon Pharmaceutical Co.
(Tokyo, Japan). Recombinant human IL-4 (13108 U/mg)
was purchased from Genzyme (Cambridge, MA, USA).
Cell culture
Renal tissues from two different patients undergoing
nephrectomy for renal cell carcinoma were used. Almost
pure (.98%) glomeruli obtained by sieve method were
digested with collagenase and inoculated into culture ves-
sels as described previously [10]. They were cultivated in
RPMI 1640 medium supplemented with 17% fetal bovine
serum (FBS) and 5 mg/ml insulin. Outgrowing cells were
subcultured with trypsin-EDTA, and expanded MC were
frozen and kept in liquid nitrogen. They were characterized
by immunofluorescent microscopy, as described previously
[10]. Cells were utilized for experiments between passages
5 and 9.
IL-6 ELISA
Human MC were grown to near-confluence in 12-well or
24-well plates. Then the cells were serum-starved by incu-
bation with RPMI 1640 medium supplemented with 0.5%
FBS and 10 mM Hepes (pH 7.4) for 48 hours. The cells were
further incubated with fresh serum-free medium containing
0.1% BSA, 10 mM Hepes, and cytokine(s) for 24 hours
unless otherwise specified. The concentrations of human
IL-6 in the supernatants were determined using an ELISA
kit (Amersham) after appropriate dilution.
Northern blot analysis
Near-confluent MC in 100 mm dishes were initially
incubated with serum-free 0.1% BSA containing RPMI
1640 medium for about 24 hours, and were further treated
with vehicle, 10 ng/ml of IL-1, 10 ng/ml of IL-4, or both for
four hours. Total RNA was isolated from the cells using a
commercial RNA purification kit (Quiagen, Germany).
Ten micrograms of the purified total RNA were electro-
phoresed on a 1% agarose gel, transferred to a nylon filter,
and hybridized with DNA probes. A 639-bp IL-6 probe was
prepared by reverse trabscription-polymerase chain reac-
tion (RT-PCR) procedure using a pair of synthesized
oligonuclotides [17] and was labeled with [a-32P]dCTP by
random priming method. Equivalent amounts of total RNA
load were assessed using a human glyceraldehyde-3-phos-
phate dehydrogenase (G3PDH) cDNA probe (Clontech,
Palo Alto, CA, USA).
IL-6 mRNA stability
The stability of IL-6 mRNA was measured by actinomy-
cin D method. Quiescent MC in 60-mm dishes were treated
with IL-1 (10 ng/ml) or IL-11IL-4 (10 ng/ml, each) for four
hours prior to addition of actinomycin D. Total RNA was
extracted at 0, 1, 2, and 4 hours following addition of
actinomycin D, and 10 mg of each sample were subjected to
Northern blot analysis as described above. Autoradio-
graphic signal density was quantitated by densitometry and
results were corrected for differences in RNA loading
determined by re-hybridization with an end-labeled 25-bp
oligonucleotide probe for 18S rRNA [18].
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared from quiescent MC after
various cytokine treatments by the method reported previ-
ously [19]. Briefly, cells were washed in phosphate-buffered
saline (PBS), scraped with a rubber policeman, pelleted,
and resuspended in lysis buffer (10 mM Tris-HCl, pH 8, 40
mM KCl, 1 mM EDTA, 1 mM dithiothreitol (DTT), 1 mM
PMSF, 3 mg/ml pepstatin, and 0.3% NP-40). After five
minutes on ice, the suspensions in 1.5 ml tubes were
centrifuged at 2,500 rpm at 4°C for four minutes. The
pellets were briefly washed in lysis buffer without NP-40.
The nuclear pellet was then resuspended in an equal-
volume of nuclear extraction buffer (20 mM Tris-HCl, pH
8.0, 720 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 25%
glycerol, 1 mM PMSF, 1 mM DTT, and 0.5 mg/ml pepstatin).
After 10 minutes on ice, the nuclear suspension was
vortexed and spun at 14,000 rpm for five minutes. The
supernatant was aliquoted and stored at 280°C. All proce-
dures described above were done at 4°C. The double-
stranded oligonucleotides containing consensus binding
sequences for NF-kB (59-AGTTGAGGGGACTTTC-
CCAGGC-39), AP1, AP2, and CREB were obtained from
Promega. The 27 bp and 14 bp double-stranded oligonu-
cleotides representing the NF-IL6-binding site of the IL-6
gene (59-GGACGTCACATTGCACAATCTTAATAA-39,
-165/-139 and 59-ACATTGCACAATCT-39, -158/-145 in
[20]) were prepared by annealing synthesized complemen-
tary oligonucleotides (Sci-Media Ltd., Tokyo, Japan).
These oligonucleotides were 59 end labeled using
[g32P]ATP (3,000 Ci/mmol) and T4 polynucleotide kinase,
run through a G-25 column, and used as probes for EMSA.
Binding reactions for NF-kB were performed by incubating
nuclear extract in 10 mM Tris-HCl, pH 7.5, 50 mM NaCl, 1
mM MgCl2, 0.5 mM EDTA, 4% glycerol, 0.5 mM DTT, 0.05
mg/ml poly(dI-dC)zpoly(dI-dC) (Pharmacia, Uppsala, Swe-
den), with an end labeled probe (approximately 35 fmol) in
a total volume of 10 ml at 4°C for 40 minutes. Samples were
electrophoresed in 4% nondenaturing acrylamide gel pre-
pared in 0.53TBE buffer. For NF-IL6, the incubation was
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conducted in 25 mM Hepes, pH 7.6, 50 mM NaCl, 1 mM
EDTA, 4% glycerol, 1 mM DTT and 0.1 mg/ml poly(dI-
dC)zpoly(dI-dC) at 4°C for 30 minutes, and the electro-
phoresis was performed on a 5% acrylamide gel prepared
in TAE buffer.
Western blot analysis
Nuclear extracts were diluted with an equal volume of
23 lysis buffer and analyzed by SDS-PAGE (10% mini-gel
with a stacking gel) under reducing conditions. Separated
proteins were transferred to nitrocellulose membrane. Af-
ter blocking with 3% BSA in PBS overnight, membranes
were incubated with primary antibody diluted 1:1000 in
PBS containing 0.05% Tween 20 for one hour. In most
cases, they were further incubated with horseradish perox-
idase-labeled anti-rabbit Ig antibody (1:2000 dilution; Am-
ersham) for one hour and visualized using ECL detection
reagents (Amersham). Some membranes were stained with
alkaline phosphatase-labeled goat anti-rabbit IgG (1:2000
dilution; Bio-Rad) and BCIP/NBT (Bio-Rad). The electro-
phoretic mobilities of the samples were compared with
calibrated prestained molecular weight standards (Bio-
Rad). Anti-p50 (NF-kB) antiserum was purchased from
Santa Cruz Biotechnology. Anti-p65 (NF-kB) antiserum
and anti-NF-IL6 antiserum were kindly provided by T.
Okamoto (Nagoya City University, Nagoya, Japan) and S.
Akira (Osaka University, Osaka, Japan), respectively.
RESULTS
IL-4 potentiates IL-6 production in human mesangial
cells
IL-6 production by human MC was estimated by mea-
suring IL-6 in the culture supernatants that accumulated
over a period of 24 hours. Without agonists, quiescent MC
produced only small amounts of IL-6 (1.24 6 1.70 pg/mg
protein/24 hr, mean 6 SD, N 5 8). The addition of 10 ng/ml
recombinant human IL-4 to the medium only marginally
stimulated IL-6 production (3.19 6 2.15 pg/mg protein/24
hr, N 5 5, P . 0.05 by t-test). On the other hand, as
reported previously [2], IL-1a treatment potently increased
IL-6 production (236 6 162 pg/mg protein/24 hr, N 5 9;
geometric mean of stimulation 5 369-fold). The potential
cooperative effect of IL-1 and IL-4 was examined by
incubating MC in the presence of both IL-1 (10 ng/ml) and
increasing concentrations of IL-4 (0.01 to 10 ng/ml). As
shown in Figure 1A, IL-4 clearly augmented the IL-1-
induced IL-6 production. This effect of IL-4 was dose-
dependent and detectable at IL-4 concentrations as low as
0.01 ng/ml. From five independent experiments, 10 ng/ml of
IL-4 potentiated IL-1-induced IL-6 production by a mean
of 3.4 6 1.5-fold.
The potentiation of IL-6 production by IL-4 was ob-
served as early as four hours after the initiation of treat-
ment (Fig. 1B). This result suggests that IL-4 might affect
IL-6 production directly, rather than through the synthesis
of other bioactive molecules.
IL-4 potentiates expression of IL-6 mRNA in IL-1-
treated mesangial cells
IL-6 mRNA expression in human MC was assessed by
Northern analysis. As shown in Figure 2A, Cells treated
with vehicle and IL-4 for four hours did not express IL-6
mRNA. In contrast, IL-1 treatment clearly induced IL-6
mRNA expression, and concurrent treatment with IL-1 and
IL-4 further increased mRNA expression. Densitometric
Fig. 1. Effects of interleukin (IL)-1 and IL-4 on IL-6 production by
human mesangial cells (MC). (A) Quiescent MC were incubated in
serum-free medium containing IL-1a (10 ng/ml) and/or IL-4 (0.01 to 10
ng/ml) for 24 hours. At the end of the incubation period, supernatants
were collected and IL-6 concentrations were quantitated by ELISA. IL-4
alone had no statistically significant effect on IL-6 release, but potentiated
the effect of IL-1a. Data shown represent one experiment. Two other
experiments gave similar results. N 5 3, *P , 0.01 compared to cells
stimulated with IL-1a alone. (B) Quiescent MC were incubated with
vehicle, IL-1a (10 ng/ml) or IL-1a (10 ng/ml)1IL-4 (10 ng/ml) for four or
eight hours. N 5 3.
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analysis of four independent experiments indicated that
IL-4 amplified the IL-1-induced IL-6 mRNA signal to
2.92 6 0.92-fold (Fig. 2B). Therefore, the effects of both
cytokines on IL-6 mRNA level appear to correspond with
those on IL-6 synthesis.
IL-4 does not change the degradation rate of IL-6 mRNA
Next, we carried out an mRNA stability assay to deter-
mine whether IL-4 altered the IL-6 mRNA degradation
rate. MC were first stimulated with IL-1 alone or IL-1 plus
IL-4 for four hours. After actinomycin D was added to stop
new mRNA synthesis, total RNA was isolated at various
time points. The decay of IL-6 mRNA was quantified by
Northern blot analysis. Figure 3 shows amounts of IL-6
mRNA expressed in relation to the initial values in each
treatment. The rate of degradation of IL-6 mRNA in cells
treated with IL-1 plus IL-4 was similar to that in cells
treated with IL-1 alone. These results suggest that the
effect of IL-4 on IL-6 gene expression is transcriptional,
rather than post-transcriptional.
IL-1, but not IL-4, rapidly activates NF-kB
Since NF-kB activation plays a key role in various
inflammatory responses, we first examined the effect of
IL-1 and IL-4 treatment on the binding activities of nuclear
extracts for NF-kB consensus site probes. Consistent with
EMSAs of other cell-types, IL-1-treated human MC nu-
clear extracts formed three specific activities (Fig. 4, ar-
rows). These bands appeared as early as 10 minutes (data
not shown), peaked at 0.5 to two hours, and were still
detectable at 12 hours after IL-1 stimulation. IL-4 treat-
ment, on the other hand, had no visible effect on NF-kB
activity at any incubation time examined.
IL-4 does not affect IL-1-induced NF-kB activation
Co-stimulation of MC with IL-1 and IL-4 for 30 minutes
(Fig. 5A), two hours (Fig. 5B), or five hours (data not
shown) had no effect on IL-1-stimulated NF-kB activation.
Competition with excess unlabeled NF-kB probe confirmed
that all three activities in IL-1-stimulated MC were NF-kB-
specific (Fig. 5C). In addition, anti-p65 antibody caused the
supershifted band. In contrast, anti-p50 antibody had little
effect on the formation of protein-DNA complexes (Fig.
5C). These data suggest that IL-1 treatment facilitates p65
Fig. 2. Effects of IL-1 and IL-4 on expression of IL-6 mRNA in human
mesangial cells (MC). (A) Quiescent MC were treated with vehicle, IL-1a
(10 ng/ml), IL-4 (10 ng/ml), or IL-11IL-4 for four hours. Total RNA was
isolated and analyzed by Northern blotting. The blot was re-probed for
G3PDH mRNA to ensure equivalent RNA loading between lanes. The
autoradiograph is representative of four independent experiments. (B)
Densitometric data in each experiment are expressed relative to the value
of IL-1 treated cells, and are shown as means 6 SD of four experiments.
Fig. 3. Effect of IL-4 on degradation of IL-6 mRNA in IL-1-activated
human mesangial cells (MC). Quiescent MC were incubated with IL-1a
(F; 10 ng/ml), or IL-1a plus IL-4 (f; 10 ng/ml) for four hours followed by
addition of actinomycin D (5 mg/ml, final). Total RNA was extracted after
0, 1, 2, and 4 hours of actinomycin D treatment and subjected to Northern
blot analysis. Autoradiographic signals of IL-6 mRNA and 18S rRNA
were quantitated by densitometry. IL-6 mRNA levels were normalized for
18S rRNA levels in each sample and expressed as percentages of time 0
values. The plotted data represent the average values of two separate
experiments.
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homodimer or p65-containing heterodimer formation in
the MC nucleus. In accord with this result, Western analysis
of nuclear extracts showed that IL-1, but not IL-4, rapidly
translocated p65 protein to the nucleus (Fig. 6). In contrast,
p50 protein was already present in the resting cell nucleus,
and IL-1 stimulation had minimal effects on translocation
of this protein (Fig. 7).
IL-1 and IL-4 treatment increases NF-IL6 motif binding
activity in mesangial cells
Similar studies were performed on nuclear extracts of
MC using NF-IL6 or C/EBP motif probes [20]. Nuclear
extracts from quiescent MC contained very weak binding
activity to the NF-IL6 motif that is present in the IL-6 gene
Fig. 4. Effects of IL-1 and IL-4 on nuclear
factor-kB (NF-kB) activity in mesangial cell
(MC) nuclear extracts. Quiescent MC were
treated with IL-1a (10 ng/ml) or IL-4 (10 ng/
ml) for the final 0.5, 2, 6, or 12 hours of a 36
hour-incubation in serum-free medium. After
preparation of nuclear extracts, binding
activities were assessed by EMSA using labeled-
NF-kB consensus oligonucleotides. Arrows
indicate specific DNA-protein complexes, which
were specifically competed by excess unlabeled
probe (Fig. 5C). Representative data are from
three independent experiments.
Fig. 5. Effects of combined treatment with IL-1
and IL-4 on nuclear factor-kB (NF-kB) activity.
Mesangial cells (MC) were treated with vehicle
(control), IL-1 (10 ng/ml), IL-4 (10 ng/ml), or
IL-11IL-4 for 30 minutes (A) or two hours (B).
NF-kB activity was analyzed as in Figure 4. The
specificity of the complexes formed with an IL-
1-treated human MC nuclear extract (HMC
NE) was examined by including 100-fold excess
unlabeled NF-kB probe, anti-p65 antiserum, or
anti-p50 antiserum in the binding mixtures (C).
Antiserum to p65 caused a supershifted band
(arrowhead). NF-kB activity in HeLa cell
nuclear extract (HeLa NE) was analyzed in
parallel as a positive control.
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promoter. IL-1 stimulation induced two specific activities
(Fig. 8, arrows), which had an apparent biphasic pattern of
formation, with the first peak at around two hours and the
second apparent at 12 hours. When cells were stimulated
with IL-4, the same bands appeared as early as 30 minutes,
and they lasted for up to 12 hours.
Synergistic stimulation of NF-IL6 activity by IL-1 and
IL-4
When MC were treated with both IL-1 and IL-4 for two
or five hours, NF-IL6 motif binding activity was further
increased compared to stimulation with a single cytokine
(Fig. 9). The increase of the binding activity was more
prominent at five hours, and synergistic action of IL-1 and
IL-4 on NF-IL6 activity was indicated. Finally, we tested
the specificity of the bands (Fig. 10). Along with nuclear
extract from cells treated with both cytokines, anti-p65
antibody, anti-NF-IL6 antibody, unlabeled 27 bp and 14 bp
NF-IL6 probes, consensus oligonucleotides for CREB,
AP2, AP1 (not shown), and NF-kB (not shown) were
variously included in the binding mixture. Of the oligonu-
cleotides examined, only the 27 bp NF-IL6 probe and a
shorter 14 bp oligonucleotide that contained the minimal
consensus binding motif for NF-IL6 displaced the bands.
Anti-NF-IL6 antibody partially attenuated the bands and
induced a weak supershifted band (arrowhead in Fig. 10).
These results suggest that the two observed bands specifi-
cally bound to the NF-IL6 motif and contained NF-IL6 and
also probably other members of the C/EBP family. In
similar competition experiments using nuclear extract from
IL-1 stimulated cells or IL-4 stimulated cells, excess 27 bp
and 14 bp unlabeled probes also displaced the bands.
However, anti-NF-IL6 antibody did not induce a discern-
ible supershifted band, most likely for relatively weak bands
evoked by single cytokine treatment (data not shown).
While we also performed Western analysis of nuclear
extracts with anti-NF-IL6 antibody, we could not clearly
identify a NF-IL6-specific protein band. This is probably
due to the low abundance of NF-IL6 protein in normal (or
non-transfected) cells.
DISCUSSION
Transfection studies have shown that the NF-kB and
NF-IL6 transcription factors play a key role in cytokine- or
Fig. 6. Effects of IL-1 and IL-4 on the nuclear
localization of nuclear factor-kB (NF-kB) p65.
Nuclear extracts were prepared from MC
treated with vehicle, IL-1a (10 ng/ml), IL-4 (10
ng/ml), or IL-11IL-4 for 30 minutes or one
hour. An equal amount of protein was loaded
onto each lane, and analyzed by Western blot
using affinity purified anti-p65 antiserum.
Representative data are from three
independent experiments.
Fig. 7. Effects of IL-1 and IL-4 on the nuclear localization of nuclear
factor-kB (NF-kB) p50. Nuclear extracts prepared from MC treated with
cytokines for 30 minutes were used for Western analysis using anti-p50
antiserum. Representative data are from two independent experiments.
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lipopolysaccharide-induced IL-6 gene expression [13–16].
Those studies showed that point or deletion IL-6 gene
mutants that have lost intact binding to either NF-kB or
NF-IL6 lacked IL-6 promoter activities. Furthermore, co-
transfection of both transcription factors resulted in their
association with the IL-6 promoter and synergistic tran-
scriptional activation [16]. These results strongly suggest
that the activation of both transcription factors are essen-
tial for maximal induction of IL-6 synthesis.
The transcription of IL-8, which often accompanies IL-6
production in various inflammatory or experimental sys-
tems, have also been reported under the cooperative
regulation of NF-kB and NF-IL6 [21–24]. While most
studies have focused on IL-6 and IL-8, the binding motifs
for both NF-kB and NF-IL6 are now known to be present
in a broad range of genes that encode most inflammation-
inducible molecules, including cytokines, adhesion mole-
cules, and so-called acute phase proteins. The list of
examples includes IL-1b, TNF-a, TGF-b2, MCP-1, granu-
locyte colony stimulating factor (G-CSF), GM-CSF, induc-
ible nitric oxide synthase, cyclooxygenase 2, cytosolic phos-
pholipase A2, serum amyloid A1, and angiotensinogen.
As many of these secretary and cellular proteins might
play a role in glomerular injury observed in nephritis, the
activation of NF-kB and NF-IL6 could be a key step in the
progression of these diseases, and both these factors are
potential therapeutic targets for GN. In fact, cyclosporine
A and glucocorticoids, which have been clinically used for
the therapy of some types of nephritis, are known to
interfere with NF-kB activation [23, 25, 26]. However,
currently little is known about the pathophysiological stim-
uli of NF-kB and NF-IL6 activation, or about the thera-
peutic effects of their inhibitors.
NF-kB is a homodimeric or heterodimeric protein com-
posed of the members of the NF-kB/rel family p65, p50,
p52, and c-Rel. Among the possible dimeric complexes,
p50/p65, the classical NF-kB, can bind various kB sites
present in many genes. In general, IL-1, TNF, and bacterial
Fig. 8. Effects of IL-1 and IL-4 on nuclear
factor (NF)-IL6 binding activity. Nuclear
extracts were prepared from quiescent MC that
were treated with IL-1a (10 ng/ml) or IL-4 (10
ng/ml) for 0.5, 2, 6, and 12 hours. The binding
activities to the NF-IL6 motif were analyzed by
EMSA using a 32P-labeled 27 bp synthetic
oligonucleotide. Arrows indicate specific
oligonucleotide-protein complexes. Two other
experiments gave similar results.
Fig. 9. Effects of combined treatment with IL-1 and IL-4 on binding
activities to NF-IL6 motif. Quiescent MC were treated with vehicle
(control), IL-1 (10 ng/ml), IL-4 (10 ng/ml), or IL-11IL-4 for two hours (A)
or five hours (B), and nuclear extracts were analyzed by EMSA.
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lipopolysaccharide are potent activators of NF-kB, but
other stimulators such as phorbol myristate acetate (PMA),
cAMP, phytohemaglutinin (PHA), IL-2, viral infection,
advanced glycosylation end products (AGE), oxidative
stress [27], and shear stress [28] have also been reported to
activate this factor. In agreement with other reports [27, 29,
30], our study showed that IL-1 activates NF-kB in cultured
MC. Supershift experiments indicated that p65 but not p50
participates in NF-kB activation. Western analysis of nu-
clear proteins indicated that p50 is constitutively present in
the nucleus of quiescent human MC and shows negligible
nuclear translocation after IL-1 stimulation. This result is in
accordance with a study using rat MC [29], but not with
another study on human MC [30]. While the reason of the
discrepant results is not clear, different culture conditions,
such as degree of confluence and a phase of cell-cycle,
might be responsible. In contrast to distinct NF-kB activa-
tion by IL-1, IL-4 treatment did not have any effect on
NF-kB activity in human MC.
Recent studies have variously reported positive or nega-
tive effects of IL-4 on NF-kB activation. In studies using
human monocytic cell lines, IL-4 suppressed NF-kB acti-
vation as well as IL-6 expression [31, 32]. However, IL-4 did
not affect IL-1-stimulated NF-kB activity in human syno-
vial fibroblasts, and even enhanced it in GM00468 dermal
fibroblasts [31]. Increased IL-6 production by IL-4 was also
reported in endothelial cells [33] and dermal fibroblasts
[34]. These studies again indicate that the cellular effects of
IL-4 are remarkably variable depending on the cell-type.
NF-IL6 is a member of the CCAAT enhancer binding
protein (C/EBP) family. The C/EBP(C/EBPa), C/EBPb
(LAP, IL-6DBP, CRP2, NF-IL6), C/EBPg (CRP3, NF-
IL6b), and C/EBPd (Ig/EBP) proteins commonly have a
basic leucine zipper domain at the C-terminal region and
form homodimers or heterodimers. The dimers bind to
similar consensus sequences T(T/G)NNG(C/T)AA(T/G)
(C/EBP binding motif) [35, 36]. C/EBPa is abundantly
expressed in liver and adipose tissue, and is thought to
maintain the differentiated functions of hepatocytes and
adipocytes. On the other hand, several studies have shown
that inflammatory stimuli, such as lipopolysaccharides,
IL-1, TNF, and IL-6, rapidly induce and also activate
NF-IL6 in various tissues and cell lines [20, 23]. Recently,
enhanced NF-IL6 activities were also recognized in vascu-
lar cells subjected to hypoxia [37] and vascular smooth
muscle cells derived from spontaneously hypertensive rats
[38].
Takeshita et al [32] and Donnelly et al [31] showed that
IL-4 had no significant effect on NF-IL6 activity in mono-
cyte cell lines. In contrast, Dokter, Koopmans and Vellenga
recently reported the strong inhibitory activity of IL-4 on
NF-IL6 binding activity in human monocytes [39]. In
human MC, we showed here that IL-4 can stimulate
NF-IL6 activity by itself and that it can augment IL-6
production in cooperation with IL-1. As IL-4 does not
modulate NF-kB activity in human MC, IL-6 production
co-stimulated by IL-1 and IL-4 probably reflects a syner-
gistically-augmented NF-IL6 binding activity by both cyto-
kines. To date, it has not been determined whether the
augmented NF-IL6 binding activity contains other mem-
bers of C/EBP family, and it is still not clear how different
cells respond to IL-4 in distinct ways. Nevertheless, our
results and those of others support that the co-ordinated
regulation of IL-6 transcription by NF-kB and NF-IL6,
which has only been shown in reporter-gene experiments
using transfected cells, is also present in normal cells.
In summary, the present study showed that IL-4 up-
regulates NF-IL6 activity and IL-6 gene expression without
affecting NF-kB activity in cultured human MC, and sug-
gests that IL-4, in the presence of NF-kB activating stimuli,
may contribute the enhanced expression of inflammation-
related molecules in the diseased glomerulus.
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Fig. 10. Specificity of binding activities to NF-IL6 motif in nuclear
extract from IL-11IL-4 stimulated cells. Nuclear extract from human MC
treated with IL-11IL-4 for five hours (HMC NE) was incubated for 30
minutes at 4°C in the presence of 100-fold excess unlabeled 27 bp NF-IL6
probes (NF-IL6 oligo), 14 bp NF-IL6 probe (NF-IL6 oligo, 14 bp), CREB,
or AP2 oligonucleotides, or 1 ml of anti-NF-IL6 antiserum or anti-p65
antiserum together with 32P-labeled 27 bp NF-IL6 probe. The two
oligonucleotide-protein complexes indicated by the arrows were markedly
displaced by cold 27 bp probe and a shorter 14 bp oligonucleotide having
a core NF-IL6 binding sequence. Anti-NF-IL6 antibody partially displaced
them and formed a weak supershifted band (arrowhead).
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